Persistence to anti-cancer treatments in the stationary to proliferating transition

Cell Cycle

Volumn 15, Issue 24, 2016, Pages 3442-3453

  Pearl Mizrahi, Sivan ^a,b   Gefen, Orit ^a   Simon, Itamar ^b   Balaban, Nathalie Q ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

cell cycle; chemotherapy; microfluidics; persistence; proliferating; quiescence; stationary

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTARABINE; VINCRISTINE; UBIQUITIN;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL KILLING; DNA CONTENT; G1 PHASE CELL CYCLE CHECKPOINT; LYMPHOBLAST; SURVIVAL RATE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FLUORESCENCE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FLUORESCENCE; G1 PHASE; HUMANS; NEOPLASMS; RESTING PHASE, CELL CYCLE; UBIQUITIN;

EID: 84995390385     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1248006     Document Type: Article

References (68)

1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46; PMID:17957189
2. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011; 473:216-20; PMID:21562562; http://dx.doi.org/10.1038/nature10069
3. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23:2233-41; PMID:19727127; http://dx.doi.org/10.1038/leu.2009.175
4. Balaban N. Persistence:mechanisms for triggering and enhancing phenotypic variability. Curr Opin Genet Dev 2011; 21:768-75; PMID:22051606; http://dx.doi.org/10.1016/j.gde.2011.10.001
5. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial Persistence as a Phenotypic Switch. Science 2004; 305:1622-5; PMID:15308767; http://dx.doi.org/10.1126/science.1099390
6. Bhuyan BK, Scheidt LG, Fraser TJ. Cell cycle phase specificity of antitumor agents. Cancer Res 1972; 32:398-407; PMID:4258018
7. Bhuyan BK, Fraser TJ, Day KJ. Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells. Cancer Res 1977; 37:1057-63; PMID:139202
8. Bigger J. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. The Lancet 1944; 244:497-500; http://dx.doi.org/10.1016/S0140-6736(00)74210-3
9. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002; 21:6249-54; PMID:12214265; http://dx.doi.org/10.1038/sj.onc.1205793
10. Blagosklonny MV. Target for cancer therapy:proliferating cells or stem cells. Leukemia 2006; 20:385-91; PMID:16357832; http://dx.doi.org/10.1038/sj.leu.2404075
11. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-5; PMID:11389048
12. Bonnet D. Normal and leukaemic stem cells. Br J Haematol 2005; 130:469-79; PMID:16098060; http://dx.doi.org/10.1111/j.1365-2141.2005.05596.x
13. Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol 2016; 14:320-30; PMID:27080241; http://dx.doi.org/10.1038/nrmicro.2016.34
14. Brock A, Chang H, Huang S. Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet 2009; 10:336-42; PMID:19337290; http://dx.doi.org/10.1038/nrg2556
15. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy:implications for clinical mechanisms of drug resistance. Ann Oncol 2001; 12:23-7; PMID:11249045; http://dx.doi.org/10.1023/A:1008389706725
16. Chen J, Li Y, Yu T-S, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488:522-6; PMID:22854781; http://dx.doi.org/10.1038/nature11287
17. Cipolleschi MG, Sbarba PD, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993; 82:2031-7; PMID:8104535
18. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008; 322:1511-6; PMID:19023046; http://dx.doi.org/10.1126/science.1160165
19. Cooper S. Rethinking synchronization of mammalian cells for cell cycle analysis. Cell Mol Life Sci CMLS 2003; 60:1099-106.
20. Dalerba P, Cho RW, Clarke MF. Cancer stem cells:models and concepts. Annu Rev Med 2007; 58:267-84; PMID:17002552; http://dx.doi.org/10.1146/annurev.med.58.062105.204854
21. De Virgilio C. The essence of yeast quiescence. Fems Microbiol Rev 2012; 36:306-39; PMID:21658086; http://dx.doi.org/10.1111/j.1574-6976.2011.00287.x
22. Drewinko B, Yang LY, Barlogie B, Trujillo JM. Cultured human tumour cells may be arrested in all stages of the cycle during stationary phase:demonstration of quiescent cells in G1, S and G2 phase. Cell Prolif 1984; 17:453-63; PMID:6467330; http://dx.doi.org/10.1111/j.1365-2184.1984.tb00604.x
23. Edelstein AD, Tsuchida MA, Amodaj N, Pinkard H, Vale RD, Stuurman N. Advanced methods of microscope control using μManager software. J Biol Methods 2014; 1:e10; PMID:25606571; http://dx.doi.org/10.14440/jbm.2014.36
24. Essers MAG, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 4:443-50; PMID:20599449; http://dx.doi.org/10.1016/j.molonc.2010.06.001
25. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14:111-22; PMID:18656424; http://dx.doi.org/10.1016/j.ccr.2008.07.002
26. Gefen O, Gabay C, Mumcuoglu M, Engel G, Balaban NQ. Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Proc Natl Acad Sci 2008; 105:6145-9; PMID:18427112; http://dx.doi.org/10.1073/pnas.0711712105
27. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103:1139-43; PMID:20877357; http://dx.doi.org/10.1038/sj.bjc.6605912
28. Giuntoli S, Rovida E, Barbetti V, Cipolleschi MG, Olivotto M, Sbarba PD. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. Leukemia 2006; 20:1291-3; PMID:16710305; http://dx.doi.org/10.1038/sj.leu.2404224
29. Graham FL, Whitmore GF. The effect of 1-β-d-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. Cancer Res 1970; 30:2627-35; PMID:5530557
30. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101:3142-9; PMID:12468427; http://dx.doi.org/10.1182/blood-2002-10-3062
31. He K, Xu T, Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 2011; 10:938-48; PMID:21518726; http://dx.doi.org/10.1158/1535-7163.MCT-10-1120
32. Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44:2259-65; PMID:6372991
33. Hill BT, Baserga R. The cell cycle and its significance for cancer treatment. Cancer Treat Rev 1975; 2:159-75; PMID:1104161; http://dx.doi.org/10.1016/S0305-7372(75)80001-6
34. Hill BT, Price LA. Letter:kinetic classifications of antitumour drugs. Br Med J 1975; 3:367-7; PMID:1156762; http://dx.doi.org/10.1136/bmj.3.5979.367
35. Hoffman RM. In vitro sensitivity assays in cancer:A review, analysis, and prognosis. J Clin Lab Anal 1991; 5:133-43; PMID:2023059; http://dx.doi.org/10.1002/jcla.1860050211
36. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94:2056-64; PMID:10477735
37. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355:1253-61; PMID:16990388; http://dx.doi.org/10.1056/NEJMra061808
38. Jensen P, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, Helledie N, and Larsen JK. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000; 33:381–395.
39. Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10:221-37; PMID:21358741; http://dx.doi.org/10.1038/nrd3373
40. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy:an important cause of treatment failure. Nat Rev Cancer 2005; 5:516-25; PMID:15965493; http://dx.doi.org/10.1038/nrc1650
41. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015; 517:209-13; PMID:25470039; http://dx.doi.org/10.1038/nature14034
42. Laconi E. The evolving concept of tumor microenvironments. BioEssays 2007; 29:738-44; PMID:17621638; http://dx.doi.org/10.1002/bies.20606
43. Laporte D, Lebaudy A, Sahin A, Pinson B, Ceschin J, Daignan-Fornier B, Sagot I. Metabolic status rather than cell cycle signals control quiescence entry and exit. J Cell Biol 2011; 192:949-57; PMID:21402786; http://dx.doi.org/10.1083/jcb.201009028
44. van Leeuwen IMM. Cyclotherapy:opening a therapeutic window in cancer treatment. Oncotarget 2012; 3:596-600; PMID:22711025; http://dx.doi.org/10.18632/oncotarget.524
45. van Leeuwen IMM, Rao B, Sachweh MCC, Laín S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle Georget Tex 2012; 11:1851-61.
46. Lewis K. Persister cells. Annu Rev Microbiol 2010; 64:357-72; PMID:20528688; http://dx.doi.org/10.1146/annurev.micro.112408.134306
47. Madoc-Jones H, Mauro F. Interphase action of vinblastine and vincristine:differences in their lethal action through the mitotic cycle of cultured mammalian cells. J Cell Physiol 1968; 72:185-95; PMID:5724569; http://dx.doi.org/10.1002/jcp.1040720306
48. Miwa S, Yano S, Kimura H, Yamamoto M, Toneri M, Matsumoto Y, Uehara F, Hiroshima Y, Murakami T, Hayashi K, et al. Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging. Cell Cycle 2014; 14:621-9; http://dx.doi.org/10.4161/15384101.2014.991604
49. Miwa S, Yano S, Kimura H, Yamamoto M, Toneri M, Murakami T, Hayashi K, Yamamoto N, Fujiwara T, Tsuchiya H, et al. Heterogeneous cell-cycle behavior in response to UVB irradiation by a population of single cancer cells visualized by time-lapse FUCCI imaging. Cell Cycle Georget Tex 2015; 14:1932-7; http://dx.doi.org/10.1080/15384101.2015.1033598
50. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 1974; 71:1286-90; PMID:4524638; http://dx.doi.org/10.1073/pnas.71.4.1286
51. Pardee AB, James LJ. Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci U S A 1975; 72:4994-8; PMID:174089; http://dx.doi.org/10.1073/pnas.72.12.4994
52. Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ. Nongenetic Individuality in the Host–Phage Interaction. PLoS Biol 2008; 6:e120; PMID:18494559; http://dx.doi.org/10.1371/journal.pbio.0060120
53. Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, Huang S. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat Commun 2013; 4:2467.
54. Pollack R, Vogel A. Isolation and characterization of revertant cell lines. J Cell Physiol 1973; 82:93-100; PMID:4354072; http://dx.doi.org/10.1002/jcp.1040820111
55. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006; 12:340-4; PMID:16428470; http://dx.doi.org/10.1158/1078-0432.CCR-05-1879
56. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11; PMID:11689955; http://dx.doi.org/10.1038/35102167
57. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A Temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141:583-94; PMID:20478252; http://dx.doi.org/10.1016/j.cell.2010.04.020
58. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, Kashiwagi S, Fukami K, Miyata T, Miyoshi H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132:487-98; PMID:18267078; http://dx.doi.org/10.1016/j.cell.2007.12.033
59. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A 2008; 105:2415-20; PMID:18272492; http://dx.doi.org/10.1073/pnas.0712168105
60. Sandler O, Mizrahi SP, Weiss N, Agam O, Simon I, Balaban NQ. Lineage correlations of single cell division time as a probe of cell-cycle dynamics. Nature 2015; 519:468-71; PMID:25762143; http://dx.doi.org/10.1038/nature14318
61. Shapiro GI, Harper JW. Anticancer drug targets:cell cycle and checkpoint control. J Clin Invest 1999; 104:1645-3; PMID:10606615; http://dx.doi.org/10.1172/JCI9054
62. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80; PMID:20371346; http://dx.doi.org/10.1016/j.cell.2010.02.027
63. Son S, Tzur A, Weng Y, Jorgensen P, Kim J, Kirschner MW, Manalis SR. Direct observation of mammalian cell growth and size regulation. Nat. Methods 2012; 9:910-2; PMID:22863882; http://dx.doi.org/10.1038/nmeth.2133
64. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009; 459:428–432.
65. Thing Mortensen Bø, Østrup Jensen P, Helledie N, Ole Iversen P, RalfkiÆR E, Knud Larsen Jø, Thorup Madsen M. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998. 102:458–464.
66. Tomura M, Sakaue-Sawano A, Mori Y, Takase-Utsugi M, Hata A, Ohtawa K, Kanagawa O, Miyawaki A. Contrasting quiescent G0 phase with mitotic cell cycling in the Mouse immune system. PLoS One 2013; 8:e73801; PMID:24066072; http://dx.doi.org/10.1371/journal.pone.0073801
67. Wang P, Robert L, Pelletier J, Dang WL, Taddei F, Wright A, Jun S. Robust growth of Escherichia coli. Curr Biol CB 2010; 20:1099-103; http://dx.doi.org/10.1016/j.cub.2010.04.045
68. Zetterberg A, Larsson O. Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc Natl Acad Sci U S A 1985; 82:5365-9; PMID:3860868; http://dx.doi.org/10.1073/pnas.82.16.5365